|
Attention providers
What changed?
The Health Care Authority (HCA) updated the COVID-19 therapies policy as follows:
- Added information on Baricitinib, which is Food and Drug Administration (FDA)-approved for hospitalized adults requiring supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). See the Medical necessity, Clinical policy, Dosage and quantity limits, and Providers sections.
- Removed tixagevimab+cilgavimab (HCPCS codes Q0220, Q0221, M0220, and M0221), retroactive to dates of service on and after January 26, 2023. This is the date the FDA revoked the emergency use authorization.
- Removed outdated billing information
- Added that when billing COVID-19 monoclonal antibodies in an outpatient prospective payment system (OPPS) setting, use revenue code 0636. This is retroactive to dates of service on and after January 1, 2022.
Therapies for COVID-19
For more details, see the revised Therapies for COVID-19 on HCA’s Provider billing guides and fee schedules webpage under COVID-19, Policies and billing guidance.
COVID-19 Fee Schedule
HCA revised the COVID-19 Fee Schedule. See HCA’s Provider billing guides and fee schedules, under COVID-19.
|
|
|
|